Financial Performance - The company's operating revenue for 2024 was ¥816,018,808.41, representing a 1.30% increase from ¥805,585,526.56 in 2023[18]. - The net profit attributable to shareholders for 2024 was -¥93,954,030.31, a decrease of 174.02% compared to -¥34,287,743.35 in 2023[18]. - The net cash flow from operating activities was -¥7,344,279.65 in 2024, a decline of 166.58% from ¥11,030,985.78 in 2023[18]. - The basic earnings per share for 2024 was -¥0.21, down 162.50% from -¥0.08 in 2023[18]. - Total assets at the end of 2024 were ¥2,203,947,708.41, a decrease of 3.40% from ¥2,281,472,772.53 at the end of 2023[18]. - The net assets attributable to shareholders decreased by 5.02% to ¥1,776,198,085.17 at the end of 2024 from ¥1,870,152,115.48 at the end of 2023[18]. - The company reported a total of ¥287.80 million in trading financial assets at the end of the period, a 12.18% increase from the beginning of the year[57]. - The company’s long-term equity investments increased from ¥15.22 million at the beginning of the year to ¥41.75 million at the end of the period, reflecting a 1.22% increase in total assets[57]. - The company’s total distributable profit is reported as -¥1,398,191,741.89, indicating a negative balance[116]. Revenue Sources - The company reported a significant increase in other business income, which rose to ¥3,878,450.29 in 2024 from ¥1,694,468.81 in 2023[19]. - The medical service business accounted for 99.52% of total revenue, with a revenue of CNY 812.14 million, up 1.03% year-on-year[41]. - The company’s gross profit margin for medical services was 7.54%, a decrease of 3.78% compared to the previous year[44]. - The company’s operating costs for medical services were CNY 750.87 million, an increase of 5.33% from CNY 712.90 million in 2023[46]. Operational Challenges - The company has indicated potential risks in its future operations, which investors should be aware of[4]. - The company reported a decrease in gross profit margin due to dynamic adjustments in medical insurance payment standards[28]. - The net profit attributable to shareholders was -66.11 million yuan in Q4, with a total of -66.05 million yuan for the year, indicating significant losses[23]. - The net cash flow from operating activities was -22.98 million yuan in Q4, highlighting cash flow challenges[23]. - The company faces risks from policy changes in the healthcare industry, increasing competition, and the need for skilled personnel[69][70]. Strategic Initiatives - The company has undergone a strategic transformation to focus primarily on providing high-quality medical services[17]. - The company is focusing on enhancing service quality and operational capabilities through strategic partnerships with renowned medical institutions[33]. - The company plans to continue integrating supply chain management to reduce costs and improve efficiency[30]. - The company plans to enhance hospital operational capabilities and efficiency while focusing on innovation and the integration of emerging medical technologies, including AI[68]. - The company is actively expanding its market presence by collaborating with leading medical institutions to enhance resource sharing and improve diagnostic capabilities[38]. Shareholder and Governance - The company has maintained a governance structure that complies with relevant laws and regulations, holding 9 board meetings and 4 supervisory meetings during the reporting period[81]. - The company operates independently from its controlling shareholder in all aspects, including business, personnel, assets, and finance[83]. - The company has implemented a transparent performance evaluation and incentive mechanism for its directors and senior management[81]. - The company has established a dedicated financial department with an independent accounting system and financial management practices[85]. - The company has successfully engaged with investors through various communication channels, ensuring transparency and information disclosure[82]. Employee Management - The company reported a total of 2,673 employees at the end of the reporting period, with 1,000 nurses and 662 doctors among them[112]. - The employee compensation structure includes basic salary, position allowances, and attendance bonuses, with annual adjustments based on industry conditions and company performance[113]. - The company implements a training plan combining internal and external training for medical staff to enhance service quality and communication skills[114]. - The company is committed to maintaining a performance-based compensation system to motivate employees effectively[113]. Compliance and Internal Control - The internal control system has been continuously improved to enhance risk prevention and support high-quality development[119]. - There were no significant internal control deficiencies identified during the reporting period[122]. - The company received a standard unqualified opinion on its internal control audit report, indicating no significant deficiencies in non-financial reporting[124]. - The company has completed rectifications for issues identified during its self-inspection of corporate governance, aiming to enhance governance standards and promote high-quality development[124]. Future Outlook - By 2025, the company aims to strengthen its hospital culture, improve quality management, and optimize clinical pathways, with a focus on high-quality development[68]. - The company has established a strategic partnership with Huawei to release the "全诊昇腾 DeepSeek model computing integration machine" in March 2025[76]. - The B-end products of the company have officially commenced multi-center clinical trials at three hospitals, with the registration application for Class II medical devices expected to be completed in the first half of 2026[73]. - The C-end product, designed for stroke patients, has entered mass production and is expected to be launched for sale in 2025[75].

此外，飞利浦星云三维影像数据中心 - 光谱云魔镜解决方案也在本次展会亮相，延续"从医生的习惯出发"的设计理念，支持访问覆盖多种主流病种的多模态 影像数据，提高临床诊断信心。同时通过统一操作界面和高效工作流程，减轻临床负担，提升工作效率。 值得一提的是，在时代浪潮下，飞利浦将可持续发展理念深度融入产品创新与服务优化的每一个环节。本次展出的BlueSeal 2.0无液氦双芯磁共振通过无液 氦磁共振技术重新定义行业标准。其自主研发的BlueSeal 2.0磁体突破传统液氦依赖，仅需传统设备0.5% 的氦气消耗量，从源头解决全球氦气短缺与失超风 险问题。截至 2024 年底，飞利浦无液氦磁共振已在全球装机超过1700台，累计节省超500 万升液氦，相当于减少 3.2 万吨二氧化碳排放。 从人工智能技术突破来看，在影像引导治疗领域，飞利浦搭载Clarity IQ的Azurion血管造影系统在中国迎来首发首展。其采用超过 500 个参数优化的高清模 型，并根据医生习惯定制图像风格，在提高图像质量的同时降低辐射剂量，让医生和患者都能从中获益。 在超声领域，飞利浦带来了EPIQ CVxi 心血管Al介入诊疗一体超声系统，采用 ...

来源：金融界 中银创新医疗混合A股票持仓前十占比合计70.60%，分别为：恒瑞医药（9.81%）、信达生物 （8.55%）、和黄医药（8.41%）、康方生物（8.35%）、康诺亚-B（8.32%）、科伦博泰生（7.87%）、 百济神州-U（6.24%）、荣昌生物（5.96%）、翰森制药（3.98%）、新诺威（3.11%）。 金融界2025年4月9日消息，中银创新医疗混合A(007718) 最新净值1.4557元，增长1.58%。该基金近1个 月收益率2.80%，同类排名22|3788；近3个月收益率27.12%，同类排名12|3756；今年来收益率20.98%， 同类排名24|3754。 简历显示：郑宁先生:中国,研究生、硕士。曾任泰康资产管理有限责任公司股票研究经理、高级股票研 究经理;中庚基金管理有限公司研究员、高级研究员(医药组组长)。2022年加入中银基金管理有限公司。 2022年7月1日担任中银创新医疗混合型证券投资基金基金经理。2022年10月13日担任中银医疗保健灵活 配置混合型证券投资基金基金经理。2023年2月28日任中银大健康股票型证券投资基金基金经理。 公开资料显示，中银创新医疗混合A基 ...

Core Insights - The report from Industrial Securities highlights the significant global market potential for surgical robots, emphasizing the high customer stickiness and sustainability of the "equipment + consumables/services" business model [1] - Intuitive Surgical, with its leading innovative products, solid market share, and stable performance, enjoys a high valuation in the US stock market [1] Company Recommendations - The report suggests paying attention to leading domestic surgical robot companies with competitive products and continuous innovation, such as MicroPort Robotics and Tianzhihang [1] - It also recommends innovative medical device companies that have entered the surgical robot business, like Kangji Medical and Sanyou Medical, as surgical robots are expected to enhance their traditional business competitive advantages [1]

AI+ 北京市连续第二年出台支持创新医药发展的专项政策。4月7日，北京市医保局等九部门发布《北京市支 持创新医药高质量发展若干措施(2025年)》(以下简称《若干措施》)，进一步加强对创新药械研、产、 审、用全链条政策支持，优化要素资源配置，培育优质创新生态，推动创新药、创新医疗（002173）器 械高质量发展。《若干措施》提出将临床试验项目启动整体用时进一步压缩至20周以内、新获批创新药 械产品数量不少于15个等创新举措。 临床 对急需创新药械建立绿色通道 《若干措施》提出，要对标国际先进水平提升临床试验效率。将临床试验项目启动整体用时压缩至20周 以内，多中心试验项目伦理审查互认率提高至90%以上。加快医企协同研究创新平台建设，推进临床试 验医企供需在线对接。实现临床研究联合体在京国家临床医学研究中心全覆盖，依托电子病历共享应用 系统实现人工智能赋能受试者招募。 为提升国际临床试验能力，要加强头部医企合作，扩大青年项目负责人培养规模，培养引进具备牵头国 际多中心临床试验能力的高水平项目负责人。对牵头完成国际多中心临床试验的医疗机构、项目负责人 给予资金支持，研究团队成员在职称职级晋升时作为重要参考。支持重 ...

4月7日，创新医疗今日收盘8.49元，下跌9.97%，最新市净率2.03，总市值37.47亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)6创新医疗-78.19-109.272.0337.47亿行业平均 45.7240.943.28142.68亿行业中值41.8333.882.5543.24亿1普瑞眼科-173.2621.662.6258.02亿2何氏眼 科-136.5041.851.3726.60亿3光正眼科-86.53205.596.9719.03亿4迪安诊断-85.2825.671.1278.93亿5南华生 物-80.12-105.4311.9529.70亿7国际医学-31.81-30.933.12113.92亿8嘉和美康-25.49-25.492.1438.24亿9皓宸 医疗-21.61-22.254.6921.00亿10美迪西-11.36-11.361.5335.89亿11和元生物-10.03-10.031.7432.58亿 来源：金融界 创新医疗管理股份有限公司是一家以提供医疗服务为主营业务的上市公司,公司下属有建华医院、康华 医院、福恬医院和明珠医院四家医疗机构，建华医院是三级甲等 ...

Core Insights - The launch of "Dajia Zhen Shou Hu Medical Insurance" by Dajia Life aims to address the increasing demand for high-quality medical services and diversified health insurance in the context of China's healthcare reform and the "Healthy China 2030" initiative [1][4] Group 1: Product Features - The insurance product focuses on inpatient medical expense reimbursement, emphasizing "innovative medical protection + quality service" to alleviate the societal issue of high medical costs and limited access to quality healthcare [1] - It includes three innovative designs: breaking down barriers to medical resources by covering public hospital special departments, international departments, and quality private hospitals; filling the gap in new technology coverage by including costs for new therapies, innovative drugs, and advanced equipment; and enhancing financial services for the elderly by extending the initial insurance age to 65 and renewal up to 100 years old [2] Group 2: Competitive Advantages - The product offers rich coverage, including general medical insurance and critical illness medical insurance, covering major medical expenses such as inpatient care, outpatient surgery, and necessary outpatient drug costs during hospitalization [3] - It supports family policies, allowing multiple family members to be insured under one policy with premium discounts, thereby reducing overall family health insurance costs [3] - The product provides comprehensive value-added services, integrating 17 health management services such as pre-consultation, direct payment during treatment, and post-recovery support, enhancing the overall healthcare experience for clients [3] Group 3: Social Value and Future Direction - As a strong supplement to basic medical insurance, commercial health insurance serves not only as a risk management tool but also as a stabilizing factor for society, helping to alleviate the financial burden of medical expenses on families [4] - Dajia Life is committed to continuous product innovation and integration of health management services, aiming to provide a richer array of health insurance products and contribute to the establishment of a comprehensive health protection ecosystem for all [4]

上海康瀚投资管理中心（有限合伙）（以下简称"康瀚投资"）作为齐齐哈尔建华医院有限责任公司（以 下简称"建华医院"）的业绩承诺人，迄今为止并未履行业绩补偿义务。因此，康瀚投资所持创新医疗管 理股份有限公司（以下简称"公司"）股份在锁定期满后，继续保持限售状态。韩猛于2024年12月11日通 过司法执行过户的方式，取得原由康瀚投资持有的450万股处于限售状态的公司股份。近日，公司收到 上海市浦东新区人民法院《民事起诉状》等，韩猛以公司未办理相关股份的解除限售手续为案由起诉公 司及公司董事。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002173 证券简称：创新医疗 公告编号：2025-011 创新医疗管理股份有限公司 关于诉讼事项的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本次诉讼的基本情况 二、有关本次诉讼的基本情况 （一）诉讼各方当事人 原告：韩猛 被告一：创新医疗管理股份有限公司 《民事起诉状》陈述的相关内容如下： "1、请求依法判令各被告停止对原告股东权利的侵害，立即为原告所持的全部4,500,000股"创新医 疗"（证券 ...

截至2025年3月28日收盘，创新医疗（002173）报收于9.14元，较上周的11.83元下跌22.74%。本周，创 新医疗3月24日盘中最高价报10.95元。3月28日盘中最低价报9.14元。本周无涨停收盘情况，共计1次跌 停收盘。创新医疗当前最新总市值41.61亿元，在医疗服务板块市值排名33/50，在两市A股市值排名 3322/5140。 本周关注点 建华医院公司就与江苏齐丰重工有限公司、齐齐哈尔建华医院、韩雪梅、韩飞、张丽、龙泯的侵权责任 纠纷，向广东省深圳市宝安区人民法院提起诉讼，并收到《受理案件通知书》。建华医院公司请求依法 判决齐丰重工、民非建华、韩雪梅赔偿财产损失26,463,966.82元；韩飞返还2,700,000.00元及自2017年4 月17日起按月利率1%计算至实际履行之日的利息；张丽返还2,300,000.00元及相应利息；龙泯返还 3,000,000.00元及相应利息；并要求各被告承担律师费、保全费、诉讼费等费用。建华医院公司在已足 额支付工程款的情况下，被法院判决需再支付工程款15,090,000.00元及逾期付款利息7,132,478.08元，最 终被强制执行26,463, ...

公开资料显示，中银创新医疗混合A基金成立于2019年11月13日，截至2024年12月31日，中银创新医疗 混合A规模20.20亿元，基金经理为郑宁。 简历显示：郑宁先生:中国,研究生、硕士。曾任泰康资产管理有限责任公司股票研究经理、高级股票研 究经理;中庚基金管理有限公司研究员、高级研究员(医药组组长)。2022年加入中银基金管理有限公司。 2022年7月1日担任中银创新医疗混合型证券投资基金基金经理。2022年10月13日担任中银医疗保健灵活 配置混合型证券投资基金基金经理。2023年2月28日任中银大健康股票型证券投资基金基金经理。 来源：金融界 金融界2025年4月3日消息，中银创新医疗混合A(007718) 最新净值1.6253元，下跌0.58%。该基金近1个 月收益率17.65%，同类排名3|2064；近3个月收益率38.89%，同类排名14|2055；今年来收益率35.07%， 同类排名14|2055。 中银创新医疗混合A股票持仓前十占比合计70.60%，分别为：恒瑞医药（9.81%）、信达生物 （8.55%）、和黄医药（8.41%）、康方生物（8.35%）、康诺亚-B（8.32%）、科伦博泰生 ...